SG11202006506TA - Methods for treating farber disease - Google Patents
Methods for treating farber diseaseInfo
- Publication number
- SG11202006506TA SG11202006506TA SG11202006506TA SG11202006506TA SG11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA SG 11202006506T A SG11202006506T A SG 11202006506TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- farber disease
- treating farber
- treating
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862625763P | 2018-02-02 | 2018-02-02 | |
PCT/IB2019/000077 WO2019150192A1 (en) | 2018-02-02 | 2019-01-31 | Methods for treating farber disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006506TA true SG11202006506TA (en) | 2020-08-28 |
Family
ID=65951809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006506TA SG11202006506TA (en) | 2018-02-02 | 2019-01-31 | Methods for treating farber disease |
Country Status (15)
Country | Link |
---|---|
US (2) | US20190240298A1 (es) |
EP (1) | EP3746115A1 (es) |
JP (2) | JP2021512853A (es) |
KR (1) | KR20200118011A (es) |
CN (1) | CN112703010A (es) |
AU (1) | AU2019214519A1 (es) |
BR (1) | BR112020015003A2 (es) |
CA (1) | CA3088225A1 (es) |
CL (1) | CL2020001856A1 (es) |
IL (1) | IL276284A (es) |
MX (1) | MX2020007501A (es) |
PH (1) | PH12020551146A1 (es) |
RU (1) | RU2020118032A (es) |
SG (1) | SG11202006506TA (es) |
WO (1) | WO2019150192A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3568154B1 (en) * | 2017-01-13 | 2023-07-12 | Icahn School of Medicine at Mount Sinai | Compositions and methods for treating farber disease |
US20220088158A1 (en) * | 2019-01-23 | 2022-03-24 | Aceragen, Inc. | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
WO2021050064A1 (en) * | 2019-09-11 | 2021-03-18 | Icahn School Of Medicine At Mount Sinai | Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012177997A1 (en) * | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
CN112126634A (zh) * | 2013-01-09 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 含用于纯化芳基硫酸酯酶a的方法 |
RU2768003C2 (ru) * | 2013-03-08 | 2022-03-22 | Джензим Корпорейшн | Интегрированное непрерывное производство терапевтических белковых лекарственных веществ |
HUE046113T2 (hu) | 2013-03-14 | 2020-02-28 | Icahn School Med Mount Sinai | Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai |
EP3568154B1 (en) | 2017-01-13 | 2023-07-12 | Icahn School of Medicine at Mount Sinai | Compositions and methods for treating farber disease |
WO2019060837A1 (en) * | 2017-09-25 | 2019-03-28 | Enzyvant Farber Gmbh | PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE |
-
2019
- 2019-01-31 CN CN201980009059.8A patent/CN112703010A/zh active Pending
- 2019-01-31 AU AU2019214519A patent/AU2019214519A1/en active Pending
- 2019-01-31 EP EP19713837.3A patent/EP3746115A1/en active Pending
- 2019-01-31 MX MX2020007501A patent/MX2020007501A/es unknown
- 2019-01-31 RU RU2020118032A patent/RU2020118032A/ru unknown
- 2019-01-31 BR BR112020015003-7A patent/BR112020015003A2/pt unknown
- 2019-01-31 JP JP2020539252A patent/JP2021512853A/ja active Pending
- 2019-01-31 US US16/263,700 patent/US20190240298A1/en not_active Abandoned
- 2019-01-31 KR KR1020207021830A patent/KR20200118011A/ko active Search and Examination
- 2019-01-31 CA CA3088225A patent/CA3088225A1/en active Pending
- 2019-01-31 SG SG11202006506TA patent/SG11202006506TA/en unknown
- 2019-01-31 WO PCT/IB2019/000077 patent/WO2019150192A1/en active Application Filing
-
2020
- 2020-07-13 CL CL2020001856A patent/CL2020001856A1/es unknown
- 2020-07-26 IL IL276284A patent/IL276284A/en unknown
- 2020-07-29 PH PH12020551146A patent/PH12020551146A1/en unknown
-
2022
- 2022-05-04 US US17/736,690 patent/US20230123505A1/en active Pending
-
2023
- 2023-06-06 JP JP2023092959A patent/JP2023113809A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3088225A1 (en) | 2019-08-08 |
JP2023113809A (ja) | 2023-08-16 |
AU2019214519A1 (en) | 2020-06-18 |
IL276284A (en) | 2020-09-30 |
BR112020015003A2 (pt) | 2020-12-29 |
CL2020001856A1 (es) | 2020-12-04 |
KR20200118011A (ko) | 2020-10-14 |
US20190240298A1 (en) | 2019-08-08 |
PH12020551146A1 (en) | 2021-06-28 |
WO2019150192A1 (en) | 2019-08-08 |
EP3746115A1 (en) | 2020-12-09 |
JP2021512853A (ja) | 2021-05-20 |
CN112703010A (zh) | 2021-04-23 |
RU2020118032A (ru) | 2022-03-02 |
US20230123505A1 (en) | 2023-04-20 |
MX2020007501A (es) | 2020-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281633A (en) | Methods for treating Huntington's disease | |
IL277190A (en) | Methods of treating HPV-related diseases | |
IL275265A (en) | Macrocyclic compounds for the treatment of disease | |
IL277333A (en) | Methods for treating eye diseases | |
IL278247B (en) | mct4 inhibitors to treat the disease | |
HK1253238A1 (zh) | 用於治療疾病的gls1抑制劑 | |
SI3393468T1 (sl) | Postopki za zdravljenje bolezni imunske pomanjkljivosti | |
IL288958A (en) | Exosomes for the treatment of diseases | |
IL276284A (en) | Methods for treating Ferber's disease | |
IL263161B (en) | New compounds for the treatment of parasitic diseases | |
IL255506A (en) | A method for treating a neurological disease | |
GB201721287D0 (en) | Treatment for inflammatory disease | |
IL269743A (en) | Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions | |
SG11202102878TA (en) | Treatment methods | |
IL281839A (en) | Treatment methods | |
EP3568154A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT FOR COLOR SYNDROME | |
IL270552A (en) | Valclospoin preparation for the treatment of proteinaceous kidney disease | |
EP3773693A4 (en) | METHODS OF TREATMENT OF AUTOIMMUNE DISEASES | |
HK1256099A1 (zh) | 用於治療移植物抗宿主病的組合物和方法 | |
IL275091A (en) | Methods for treating Gaucher's disease | |
ZA202001927B (en) | Method for treating tnf alpha-related diseases | |
EP3796978A4 (en) | METHOD OF TREATING CARDIOVASCULAR DISEASE | |
EP3577224A4 (en) | NEW TREATMENT FOR NEAT1-ASSOCIATED DISEASES | |
IL246608A0 (en) | Preparations and methods for treating heart disease | |
EP4058063A4 (en) | METHODS OF TREATMENT OF DISEASES |